Prior to its acquisition, temporary pullbacks or downward movements in Nuvalent stock were occasionally triggered by investor profit-taking following strong clinical data readouts, broader macroeconomic biotechnology sector rotations, or minor market hesitations regarding trial subset details. Ultimately, its public trading trajectory concluded following its definitive acquisition by GSK at a substantial cash premium per share.